These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16810620)

  • 1. Treatment of polycythemia vera.
    Silver RT
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):437-42. PubMed ID: 16810620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and therapy of polycythemia vera.
    Lengfelder E; Merx K; Hehlmann R
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and intensity of treatment in polycythemia vera.
    Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
    N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G
    Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management in polycythemia vera.
    Gilbert HS
    Semin Hematol; 2001 Jan; 38(1 Suppl 2):25-8. PubMed ID: 11242599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T; Finazzi MC; Finazzi G
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to manage polycythemia vera.
    Passamonti F
    Leukemia; 2012 May; 26(5):870-4. PubMed ID: 22157736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
    Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
    Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
    Thurmes PJ; Steensma DP
    Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
    Stein BL; Oh ST; Berenzon D; Hobbs GS; Kremyanskaya M; Rampal RK; Abboud CN; Adler K; Heaney ML; Jabbour EJ; Komrokji RS; Moliterno AR; Ritchie EK; Rice L; Mascarenhas J; Hoffman R
    J Clin Oncol; 2015 Nov; 33(33):3953-60. PubMed ID: 26324368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.